Company’s year-end TULSA-PRO installed base stood at 78 systems; qualified sales pipeline grew to 97 new systemsTORONTO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) ...
(NASDAQ:PROF; TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased ...
Profound Medical Corp's TULSA-PRO system has the potential to disrupt the surgical treatment of prostate disease. The company is delivering solid growth in recurring and capital revenues. Despite high ...
Profound Medical ( ($TSE:PRN) ) has shared an announcement. Profound Medical announced that The Johns Hopkins Hospital has performed its first ...
Doctors perform transurethral ultrasound ablation (TULSA) procedures using the TULSA-PRO system. This treats people with prostate disease, including prostate cancer or an enlarged prostate. New ...
TORONTO, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, ...
Tulsa's new USL PRO team officially has a name. And it's one with which Tulsans will already be familiar. The team announced on Wednesday it will be called the Tulsa Roughnecks FC, after that name ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback